ADAPTIVE BIOTECHNOLOGIES CORPORATION Increase (Decrease) in Contract with Customer, Liability
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Increase (Decrease) in Contract with Customer, Liability of $7.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $3.66M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was $4.00M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was $3.66M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$32.79M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in contract with customer, liability for fiscal 2025 was -$36.74M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in contract with customer, liability for fiscal 2024 was -$10.48M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in contract with customer, liability for fiscal 2023 was -$29.29M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in contract with customer, liability for fiscal 2022 was -$56.50M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $7.66M 10-Q · filed 2026-08-04 | $11.32M derived: sum of 3 quarters · filed 2026-08-04 | -$21.47M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $4.00M 10-Q · filed 2026-05-05 | $7.66M derived: sum of 2 quarters · filed 2026-05-05 | -$25.13M derived: sum of 3 quarters · filed 2026-05-05 | -$29.41M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $3.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$29.13M derived: sum of 2 quarters · filed 2026-02-26 | -$33.42M derived: sum of 3 quarters · filed 2026-08-04 | -$36.74M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$32.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$37.08M derived: sum of 2 quarters · filed 2026-08-04 | -$40.40M 10-Q · filed 2025-11-05 | -$42.09M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$4.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$7.61M 10-Q · filed 2026-08-04 | -$9.30M derived: sum of 3 quarters · filed 2026-08-04 | -$15.74M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$3.33M 10-Q · filed 2026-05-05 | -$5.02M derived: sum of 2 quarters · filed 2026-05-05 | -$11.45M derived: sum of 3 quarters · filed 2026-05-05 | -$11.41M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$8.12M derived: sum of 2 quarters · filed 2026-02-26 | -$8.09M derived: sum of 3 quarters · filed 2026-02-26 | -$10.48M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$6.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$6.39M derived: sum of 2 quarters · filed 2025-11-05 | -$8.79M 10-Q · filed 2025-11-05 | -$14.90M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$2.35M 10-Q · filed 2025-08-05 | -$8.46M derived: sum of 3 quarters · filed 2026-02-26 | -$17.74M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$2.39M 10-Q · filed 2025-05-01 | -$8.50M derived: sum of 2 quarters · filed 2026-02-26 | -$17.78M derived: sum of 3 quarters · filed 2026-02-26 | -$23.20M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$6.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$15.39M derived: sum of 2 quarters · filed 2026-02-26 | -$20.80M derived: sum of 3 quarters · filed 2026-02-26 | -$29.29M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$9.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$14.69M derived: sum of 2 quarters · filed 2024-11-07 | -$23.18M 10-Q · filed 2024-11-07 | -$35.66M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$5.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$13.90M 10-Q · filed 2024-08-01 | -$26.38M derived: sum of 3 quarters · filed 2025-03-03 | -$46.22M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$8.49M 10-Q · filed 2024-05-07 | -$20.96M derived: sum of 2 quarters · filed 2025-03-03 | -$40.81M derived: sum of 3 quarters · filed 2025-03-03 | -$54.17M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$12.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$32.32M derived: sum of 2 quarters · filed 2025-03-03 | -$45.68M derived: sum of 3 quarters · filed 2025-03-03 | -$56.50M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$19.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$33.21M derived: sum of 2 quarters · filed 2023-11-09 | -$44.02M 10-Q · filed 2023-11-09 | -$55.40M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$13.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$24.17M 10-Q · filed 2023-08-02 | -$35.56M derived: sum of 3 quarters · filed 2024-02-29 | -$48.16M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$10.81M 10-Q · filed 2023-05-03 | -$22.19M derived: sum of 2 quarters · filed 2024-02-29 | -$34.80M derived: sum of 3 quarters · filed 2024-02-29 | -$54.31M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$11.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$23.98M derived: sum of 2 quarters · filed 2024-02-29 | -$43.49M derived: sum of 3 quarters · filed 2024-02-29 | -$57.73M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$12.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$32.11M derived: sum of 2 quarters · filed 2022-11-03 | -$46.34M 10-Q · filed 2022-11-03 | -$62.45M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | -$19.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$33.74M 10-Q · filed 2022-08-03 | -$49.85M derived: sum of 3 quarters · filed 2023-02-14 | -$59.97M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | -$14.23M 10-Q · filed 2022-05-04 | -$30.34M derived: sum of 2 quarters · filed 2023-02-14 | -$40.46M derived: sum of 3 quarters · filed 2023-02-14 | -$50.70M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | -$16.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | -$26.22M derived: sum of 2 quarters · filed 2023-02-14 | -$36.46M derived: sum of 3 quarters · filed 2023-02-14 | -$43.39M 10-K · filed 2023-02-14 |
| 2020-09-30 | -$10.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$20.36M derived: sum of 2 quarters · filed 2021-11-03 | -$27.28M 10-Q · filed 2021-11-03 | -$36.56M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | -$10.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$17.16M 10-Q · filed 2021-08-04 | -$26.45M derived: sum of 3 quarters · filed 2022-02-15 | -$38.95M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | -$6.93M 10-Q · filed 2021-05-05 | -$16.21M derived: sum of 2 quarters · filed 2022-02-15 | -$28.71M derived: sum of 3 quarters · filed 2022-02-15 | -$36.08M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | -$9.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | -$21.79M derived: sum of 2 quarters · filed 2022-02-15 | -$29.15M derived: sum of 3 quarters · filed 2022-02-15 | $266.93M 10-K · filed 2022-02-15 |
| 2019-09-30 | -$12.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$19.87M derived: sum of 2 quarters · filed 2020-11-10 | $276.21M 10-Q · filed 2020-11-10 | $271.96M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | -$7.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $288.71M 10-Q · filed 2020-08-10 | $284.46M derived: sum of 3 quarters · filed 2021-02-24 | $282.64M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $296.08M 10-Q · filed 2020-05-12 | $291.83M derived: sum of 2 quarters · filed 2021-02-24 | $290.01M derived: sum of 3 quarters · filed 2021-02-24 | |
| 2018-12-31 | -$4.25M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$6.07M derived: sum of 2 quarters · filed 2021-02-24 | -$649.00K 10-K · filed 2021-02-24 | |
| 2018-09-30 | -$1.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $3.60M 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $5.42M 10-Q · filed 2019-08-13 | |||
| 2017-12-31 | $2.53M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |